Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Maaseik – page 29

1 146 clinical trials in Maaseik, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Maaseik at a glance
1 146
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 146 trials in Maaseik

Open in trial search

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen Cilag International

Study on Venetoclax and Rituximab for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on the Effect and Safety of Autologous Mesoangioblasts for Patients with Mitochondrial Myopathy Due to m.3243A>G Mutation

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Autologous Muscle Precursor Cells
  • Sponsor:University Hospital Maastricht

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Gastric cancer

Recruiting

Study on Pre-operative Capecitabine, Oxaliplatin, Docetaxel, and Atezolizumab for Patients with Resectable Gastric or Gastro-esophageal Junction Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Modified Osimertinib Dosing with Cobicistat for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:University Hospital Maastricht

Study on Early Stage Follicular Lymphoma: Evaluating Radiotherapy with Rituximab or Obinutuzumab for Patients with Early Stage Nodal Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:Universitair Medisch Centrum Groningen

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Maaseik

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management strategies in primary care settings. The trials investigate optimal approaches for patients with chronic PPI use without long-term indications.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Control Strategies

These studies evaluate the effectiveness of different deprescribing approaches, including on-demand usage and alternative therapeutic options, compared to traditional dose reduction methods.

02 Primary Care Innovation

Research exploring patient-centered approaches in medication management, specifically examining alternative treatment strategies for common gastrointestinal conditions in the primary care setting.

  • Medication Optimization
  • Alternative Treatment Methods
  • Patient-Centered Care

The studies aim to enhance treatment protocols while maintaining effective symptom control and improving patient outcomes.

03 Therapeutic Strategy Evaluation

Comparative research examining different therapeutic approaches for managing chronic gastrointestinal symptoms, including innovative medication schedules and alternative formulations.

  • Comparative Effectiveness
  • Treatment Optimization
  • Long-term Management

These trials focus on developing evidence-based strategies for optimal medication management in primary care practice.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.